BfArM - Federal Institute for Drugs and Medical Devices

Navigation and service

Public databases

DMIDS Public Part

Sponsors and persons obligated to notify have the option to enter and edit their data in the German Medical Devices Information and Database System (DMIDS). At this point they are only able to see their own content.
In addition, the following fact databases are available to the public for general search within the DMIDS (public part): Medical Devices Notifications (MPA), In Vitro Diagnostic Medical Devices Notifications (MPIVDA) and address databases with addresses of the persons reporting and of the competent authorities.

Login DMIDS Public Part and guidances

DMIDS Public Part

Flat fees for database search

Quotations at a charge will only be possible via weekly or annual flat fees. By ordering a flat fee offer, you have access to the public databases.
You can book the flat fees via our online system. Extensions and additional bookings of flat fees are also possible here.
Access to the databases is possible immediately after a successful purchase of a flat fee.
You can pay by credit card, Giropay or by invoice.

Prices for users within Germany

Table 1: Prices for flat fees, valid from 01.01.2021, including the german VAT of 19%.

Database(s)Term 1 up to 9 weeksTerm of 1 year
AMIce Public Part59,49 € / week594,99 € / year
ABDA database*83,30 € / weekX
Medical devices databases Public Part14,28 € / week142,80 € / year

* Please note that the ABDA database is only accessible to health care professionals within the meaning of § 2 Heilmittelwerbegesetz.

Prices for users outside of Germany

For private customers within the EU, prices are increased by the VAT rate applicable in their country.

Table 2: Prices for flat fees, valid from 02.01.2019, excluding VAT

Database(s)Term 1 up to 9 weeksTerm of 1 year
AMIce Public Part49,99 € / week499,99 € / year
ABDA database*70,00 € / weekX
Medical devices databases Public Part12,00 € / week120,00 € / year

* Please note that the ABDA database is only accessible to health care professionals within the meaning of § 2 Heilmittelwerbegesetz.